Compare IQ & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQ | ARDX |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2017 | 2014 |
| Metric | IQ | ARDX |
|---|---|---|
| Price | $1.42 | $6.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $2.91 | ★ $15.14 |
| AVG Volume (30 Days) | ★ 8.2M | 3.0M |
| Earning Date | 05-20-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | $0.45 | $37.75 |
| Revenue Next Year | $3.76 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $3.50 |
| 52 Week High | $2.76 | $8.40 |
| Indicator | IQ | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 59.74 |
| Support Level | $1.19 | $5.49 |
| Resistance Level | $2.16 | $6.70 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 92.00 | 87.88 |
Iqiyi is a streaming video-on-demand company in China that generates revenue mostly on a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.